CASI Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CASI Nasdaq 2836 www.casipharmaceuticals.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals Provides Business and Clinical Update - May 19th, 2025 7:00 am
CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results - May 16th, 2025 6:00 am
CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China - May 12th, 2025 6:00 am
CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement - May 7th, 2025 6:00 am
CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company - Apr 3rd, 2025 6:00 am
CASI Pharmaceuticals Full Year 2024 Earnings: US$2.56 loss per share (vs US$2.02 loss in FY 2023) - Apr 2nd, 2025 4:20 am
CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results - Mar 31st, 2025 6:15 am
This CASI Pharmaceuticals Insider Increased Their Holding By 65% Last Year - Feb 6th, 2025 6:44 am
CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia - Jan 6th, 2025 6:00 am
CASI Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Nov 17th, 2024 5:09 am
CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results - Nov 15th, 2024 6:00 am
CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia - Oct 24th, 2024 6:00 am
CASI Pharmaceuticals (NASDAQ:CASI) shareholders are still up 129% over 1 year despite pulling back 22% in the past week - Sep 26th, 2024 11:18 am
CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE - Sep 4th, 2024 6:00 am
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS - Aug 16th, 2024 6:00 am
CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS - Jul 19th, 2024 3:30 pm
CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP - Jul 8th, 2024 5:30 am